Trial Profile

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Mar 2025 Results(n=200) comparing the safety profiles of Ibrutinib and Zanubrutinib, in patients with chronic lymphocytic leukemia (CLL), published in the Hematological Oncology
01 Oct 2024 Results from the subgroup of Chinese patients, published in the Annals of Hematology.
24 May 2024 According to a BeiGene Media Release, the presentation of a network meta-analysis evaluating the relative efficacy of available treatments for patients with high-risk relapsed/refractory (R/R) CLL from clinical trials ALPINE, ELEVATE-RR and ASCEND will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com